Faculty

Back to Index
Susan L Groshen, PhD
Professor of Research Preventive Medicine
Preventive Medicine
NTT 4425A 1441 Eastlake Avenue Health Sciences Campus Los Angeles
+1 323 865 0375

Overview

Dr. Groshen is involved in the evaluation of new drugs and therapeutic strategies for treating cancer. As the statistician overseeing the clinical trials program at the USC/Norris Comprehensive Cancer Center, Dr. Groshen is responsible for statistical and design issues and is involved in the planning of data management. As studies are completed, she is responsible for statistical analysis of the results.

Publications

Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 Aug; 63(8):1349-56. View in: PubMed

Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. View in: PubMed

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. View in: PubMed

Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, Jhaveri N, Groshen SL, Olenyuk BZ, Chen TC, Hofman FM, Shih JC. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget. 2016 Mar 22; 7(12):13842-53. View in: PubMed

Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R, Alexopoulos S. Kidney transplantation in the Hispanic population. Clin Transplant. 2016 Feb; 30(2):118-23. View in: PubMed

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16(1):360. View in: PubMed

Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, Li Z, Schones DE, Frenkel B. RUNX1 prevents oestrogen-mediated AXIN1 suppression and ß-catenin activation in ER-positive breast cancer. Nat Commun. 2016; 7:10751. View in: PubMed

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63. View in: PubMed

Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. J Surg Oncol. 2015 Aug; 112(2):125-32. View in: PubMed

Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015 Jul 7; 22(1):86-99. View in: PubMed

von Rundstedt FC, Mata DA, Groshen S, Stein JP, Skinner DG, Stadler WM, Cote RJ, Kryvenko ON, Godoy G, Lerner SP. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9. View in: PubMed

Stany MP, Stone PJ, Felix JC, Amezcua CA, Groshen S, Ye W, Kyser KL, Howard RS, Zahn CM, Muderspach LI, Lentz SE, Chernofsky MR. Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. Int J Gynecol Pathol. 2015 Jul; 34(4):379-84. View in: PubMed

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. View in: PubMed

Mata DA, Groshen S, Von Rundstedt FC, Skinner DG, Stadler WM, Cote RJ, Stein JP, Lerner SP. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8. View in: PubMed

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. (131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. View in: PubMed

Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression. PLoS One. 2015; 10(2):e0117758. View in: PubMed

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. View in: PubMed

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7. View in: PubMed

Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential Effects of RUNX2 on the Androgen Receptor in Prostate Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and Subsequent Invasiveness. Cancer Res. 2014 May 15; 74(10):2857-68. View in: PubMed

Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. View in: PubMed

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. View in: PubMed

Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother. 2013 Jun; 36(5):319-29. View in: PubMed

Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, Cote RJ. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer. 2013 Feb 15; 119(4):756-65. View in: PubMed

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. J Nucl Med. 2012 Jul; 53(7):1155-63. View in: PubMed

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 1; 18(9):2679-86. View in: PubMed

Ting MC, Liao CP, Yan C, Jia L, Groshen S, Frenkel B, Roy-Burman P, Coetzee GA, Maxson R. An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Dis Model Mech. 2012 May; 5(3):366-74. View in: PubMed

Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. View in: PubMed

Kaur P, Ward B, Saha B, Young L, Groshen S, Techy G, Lu Y, Atkinson R, Taylor CR, Ingram M, Imam SA. Human breast cancer histoid: an in vitro 3-dimensional co-culture model that mimics breast cancer tissue. J Histochem Cytochem. 2011 Dec; 59(12):1087-100. View in: PubMed

Sposto R, Groshen S. A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. Contemp Clin Trials. 2011 Sep; 32(5):694-703. View in: PubMed

Birkhahn M, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Long-term outcome in patients with a Gleason score = 6 prostate cancer treated by radical prostatectomy. BJU Int. 2011 Sep; 108(5):660-4. View in: PubMed

Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. View in: PubMed

Dong D, Stapleton C, Luo B, Xiong S, Ye W, Zhang Y, Jhaveri N, Zhu G, Ye R, Liu Z, Bruhn KW, Craft N, Groshen S, Hofman FM, Lee AS. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011 Apr 15; 71(8):2848-57. View in: PubMed

Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011 Feb 1; 128(3):726-31. View in: PubMed

Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. View in: PubMed

Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One. 2011; 6(12):e28141. View in: PubMed

Bernstein I, Byun HM, Mohrbacher A, Douer D, Gorospe G, Hergesheimer J, Groshen S, O'Connell C, Yang AS. A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. View in: PubMed

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 1; 70(15):1692-700. View in: PubMed

Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV, Cortessis VK, Coetzee GA, Pike MC, Gago-Dominguez M. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis. 2010 Nov; 31(11):1964-71. View in: PubMed

Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010 Oct 15; 16(20):5011-8. View in: PubMed

Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. View in: PubMed

Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 1; 70(12):1359-70. View in: PubMed

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. View in: PubMed

Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9. View in: PubMed

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55. View in: PubMed

Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol. 2010 Jan; 57(1):12-20. View in: PubMed

Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009 Nov 10; 27(32):5343-9. View in: PubMed

Shuangshoti S, Thorner PS, Ruangvejvorachai P, Saha B, Groshen S, Taylor CR, Malhotra S, Imam SA. J1-31 protein expression in astrocytes and astrocytomas. Neuropathology. 2009 Oct; 29(5):521-7. View in: PubMed

Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens. Anal Biochem. 2009 Sep 15; 392(2):117-25. View in: PubMed

Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009 Aug 20; 27(24):3929-37. View in: PubMed

LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics. 2009; 2:67. View in: PubMed

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. View in: PubMed

Jadvar H, Ye W, Groshen S, Conti PS. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008 Nov; 22(9):787-93. View in: PubMed

Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, Jones LW, Imam SA. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. Prostate. 2008 Nov 1; 68(15):1681-8. View in: PubMed

Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata DK, Conti DV, Gago-Dominguez M. Water intake and bladder cancer risk in Los Angeles County. Int J Cancer. 2008 Oct 1; 123(7):1649-56. View in: PubMed

Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, Tsao-Wei DD, Groshen S, Jones PA. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res. 2008 Aug 1; 68(15):6208-14. View in: PubMed

Goebell PJ, Groshen SL, Schmitz-Dräger BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008 Feb; 26(1):5-11. View in: PubMed

Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. View in: PubMed

Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM, Lee AS. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008 Jan 15; 68(2):498-505. View in: PubMed

Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, Jones LW, Imam SA. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate. 2008 Jan 1; 68(1):78-84. View in: PubMed

Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. View in: PubMed

Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 1; 26(1):76-82. View in: PubMed

George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007 Dec 1; 25(34):5352-8. View in: PubMed

Saha B, Chaiwun B, Imam SS, Tsao-Wei DD, Groshen S, Naritoku WY, Imam SA. Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res. 2007 Nov-Dec; 27(6B):3903-8. View in: PubMed

Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer. 2007 Nov; 58(2):220-30. View in: PubMed

Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007 Oct; 38(10):1547-52. View in: PubMed

Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25(24):3712-8. View in: PubMed

Jiang X, Castelao JE, Groshen S, Cortessis VK, Ross RK, Conti DV, Gago-Dominguez M. Alcohol consumption and risk of bladder cancer in Los Angeles County. Int J Cancer. 2007 Aug 15; 121(4):839-45. View in: PubMed

Saha B, Chaiwun B, Tsao-Wei DD, Groshen SL, Naritoku WY, Atkinson RD, Taylor CR, Imam SA. Telomerase and markers of cellular proliferation are associated with the progression of cervical intraepithelial neoplasia lesions. Int J Gynecol Pathol. 2007 Jul; 26(3):214-22. View in: PubMed

Kang TY, Nichols P, Skinner E, Groshen S, Valin G, Ye W, Raghavan D. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response. BJU Int. 2007 May; 99(5):1024-7. View in: PubMed

Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, Groshen S, Lieskovsky G, Skinner DG. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol. 2007 Mar; 177(3):876-81; discussion 881-2. View in: PubMed

Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007 Jan 1; 13(1):215-22. View in: PubMed

Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. View in: PubMed

Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006 Nov; 176(5):2025-31; discussion 2031-2. View in: PubMed

Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006 Aug 15; 66(16):7849-53. View in: PubMed

Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. View in: PubMed

Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol. 2006 Aug; 176(2):493-8; discussion 498-9. View in: PubMed

Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. View in: PubMed

Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006 Jul; 78(3):271-6. View in: PubMed

Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18):2735-42. View in: PubMed

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. View in: PubMed

Pike BL, Groshen S, Hsu YH, Shai RM, Wang X, Holtan N, Futscher BW, Hacia JG. Comparisons of PCR-based genome amplification systems using CpG island microarrays. Hum Mutat. 2006 Jun; 27(6):589-96. View in: PubMed

Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006 May 1; 106(9):2021-7. View in: PubMed

Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan; 7(1):67-88. View in: PubMed

Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2006 Jan 1; 106(1):172-9. View in: PubMed

Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005 Jul; 5(2):124-31. View in: PubMed

Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005 Jul; 174(1):93-6. View in: PubMed

Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, Daneshmand S, Skinner EC, Skinner DG. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005 Jul; 174(1):103-6. View in: PubMed

Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20; 23(15):3536-44. View in: PubMed

Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol. 2005 Apr; 173(4):1163-8. View in: PubMed

Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy. J Neurooncol. 2005 Apr; 72(2):185-9. View in: PubMed

Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005 Mar; 200(3):336-44. View in: PubMed

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005 Feb 1; 23(4):741-50. View in: PubMed

Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res. 2005 Feb 1; 11(3):1237-46. View in: PubMed

Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallböhmer D, Rhodes K, Lenz HJ. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):600-5. View in: PubMed

Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):413-5. View in: PubMed

Karaman MW, Groshen S, Lee CC, Pike BL, Hacia JG. Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucleic Acids Res. 2005; 33(3):e33. View in: PubMed

Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology. 2004 Dec 14; 63(11):2159-61. View in: PubMed

Chang A, Cai J, Miranda G, Groshen S, Skinner D, Stein JP. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol. 2004 Dec; 172(6 Pt 1):2182-6. View in: PubMed

Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. View in: PubMed

Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Barton Grossman H, Waldman F, Cote RJ. The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol. 2004 Jul-Aug; 22(4):277-84. View in: PubMed

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Anticancer Res. 2004 Jul-Aug; 24(4):2391-400. View in: PubMed

Daneshmand S, Stein JP, Lesser T, Quek ML, Nichols PW, Miranda G, Cai J, Groshen S, Skinner EC, Skinner DG. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol. 2004 Jul; 172(1):81-4. View in: PubMed

Lentz SE, Muderspach LI, Felix JC, Ye W, Groshen S, Amezcua CA. Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol. 2004 Jun; 103(6):1204-10. View in: PubMed

Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, Laug WE. Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest. 2004 Jun; 84(6):667-78. View in: PubMed

Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004 Apr 13; 62(7):1210-2. View in: PubMed

Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004 Mar 15; 22(6):1007-13. View in: PubMed

Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004 Mar 1; 64(5):1675-86. View in: PubMed

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. View in: PubMed

Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH. Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer. 2004 Jan 23; 3:5. View in: PubMed

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 1; 98(5):955-61. View in: PubMed

Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003 Jul; 170(1):35-41. View in: PubMed

Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003 Apr; 9(4):1301-12. View in: PubMed

Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol. 2003 Apr; 121(1):139-42. View in: PubMed

Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol. 2003 Mar; 1(3):162-6. View in: PubMed

Stapfer M, Hu J, Wei D, Groshen S, Beart RW. Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery. J Surg Oncol. 2003 Feb; 82(2):121-30; discussion 131. View in: PubMed

Yang X, Groshen S, Formenti SC, Davidson NE, Press MF. P7 antigen expression in human breast cancer. Clin Cancer Res. 2003 Jan; 9(1):201-6. View in: PubMed

Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, Hölscher AH, Danenberg KD, Danenberg PV. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7. View in: PubMed

Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20; 277(51):49531-7. View in: PubMed

Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S. Potential role of platelet FcgammaRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis. 2002 Oct; 164(2):261-7. View in: PubMed

Baltayan A, Naritoku WY, Chaiwun B, Tsao-Wei DD, Groshen S, Hern RA, Gusterson BA, Taylor CR, Imam SA. LEA. 135 expression: identifies low-risk patients with breast ductal carcinoma in situ. Anticancer Res. 2002 Sep-Oct; 22(5):2933-7. View in: PubMed

Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002 Aug; 67(9):799-813. View in: PubMed

Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002 Jun 19; 94(12):936-42. View in: PubMed

Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 1; 52(2):397-405. View in: PubMed

Brabender J, Danenberg KD, Metzger R, Schneider PM, Lord RV, Groshen S, Tsao-Wei DD, Park J, Salonga D, Hölscher AH, Danenberg PV. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):438-43. View in: PubMed

Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002 Jan; 17(1):46-9. View in: PubMed

Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology. 2002 Jan; 59(1):97-102. View in: PubMed

Powered bySC CTSI